The Misuse of Drugs Regulations 2001

PART IIU.K. [F1Controlled Drugs Excepted From the Prohibition on Possession; Excluded from the Application of Offences Arising from the Prohibition on Importation and Exportation when Carried Out in Person for Administration to That Person; and Subject to the Requirements of Regulations 22, 23, 26 and 27]

Textual Amendments

1.  The following substances, namely—U.K.

  • [F25α–Androstane–3,17–diol]

  • [F2Androst-4-ene-3,17-diol]

  • [F21–Androstenediol]

  • [F21–Androstenedione]

  • [F34-Androstene-3, 17-dione]

  • [F45–Androstenedione]

  • [F35-Androstene-3, 17 diol]

  • Atamestane

  • Bolandiol

  • Bolasterone

  • Bolazine

  • Boldenone

  • [F5Boldione]

  • Bolenol

  • Bolmantalate

  • Calusterone

  • 4-Chloromethandienone

  • Clostebol

  • [F6Danazol]

  • [F6Desoxymethyltestosterone]

  • [F7Dienedione (estra-4, 9-diene-3,17-dione)]

  • Drostanolone

  • Enestebol

  • Epitiostanol

  • Ethyloestrenol

  • Fluoxymesterone

  • Formebolone

  • Furazabol

  • [F8Gestrinone]

  • [F83–Hydroxy–5α–androstan–17–one]

  • Mebolazine

  • Mepitiostane

  • Mesabolone

  • Mestanolone

  • Mesterolone

  • Methandienone

  • Methandriol

  • Methenolone

  • Methyltestosterone

  • Metribolone

  • Mibolerone

  • Nandrolone

  • [F919–Norandrostenedione]

  • [F1019-Nor-4-Androstene-3, 17-dione]

  • [F1019-Nor-5-Androstene-3, 17 diol]

  • [F1119–Norandrosterone]

  • Norboletone

  • Norclostebol

  • Norethandrolone

  • [F1219–Noretiocholanolone]

  • Ovandrotone

  • Oxabolone

  • Oxandrolone

  • Oxymesterone

  • Oxymetholone

  • Prasterone

  • Propetandrol

  • [F13Prostanozol]

  • Quinbolone

  • Roxibolone

  • Silandrone

  • Stanolone

  • Stanozolol

  • Stenbolone

  • Testosterone

  • [F14Tetrahydrogestrinone]

  • Thiomesterone

  • Trenbolone

Textual Amendments

F3Words in Sch. 4 Pt. 2 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(4)(a)

F10Words in Sch. 4 Pt. 2 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(4)(b)

2.  Any compound (not being Trilostane or a compound for the time being specified in paragraph 1 of this Part of this Schedule) structurally derived from 17-hydroxyandrostan-3-one or from 17-hydroxyestran-3-one by modification in any of the following ways, that is to say -U.K.

(a)by further substitution at position 17 by a methyl or ethyl group;

(b)by substitution to any extent at one or more of positions 1, 2, 4, 6, 7, 9, 11 or 16, but at no other position;

(c)by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than two ethylenic bonds in any one carbocyclic ring;

(d)by fusion of ring A with a heterocyclic system.

3.  Any substance which is an ester or ether (or, where more than one hydroxyl function is available, both an ester and an ether) of a substance specified in paragraph 1 or described in paragraph 2 of this Part of this Schedule.U.K.

4.  The following substances, namely—U.K.

  • Chorionic Gonadotrophin (HCG)

  • Clenbuterol

  • Non-human chorionic gonadotrophin

  • Somatotropin

  • Somatrem

  • Somatropin

  • [F15Zeranol]

  • [F15Zilpaterol]

Textual Amendments

5.  Any stereoisomeric form of a substance specified or described in any of paragraphs 1 to 4 of this Part of this Schedule.U.K.

6.  Any salt of a substance specified or described in any of paragraphs 1 to 5 of this Part of this Schedule.U.K.

7.  Any preparation or other product containing a substance or product specified or described in any of paragraphs 1 to 6 of this Part of this Schedule, not being a preparation specified in Schedule 5.U.K.